HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer

被引：0

作者：

Sawada, Kentaro ^{[1
]}

Kawamoto, Yasuyuki ^{[2
]}

Yuki, Satoshi ^{[3
]}

Nakamura, Michio ^{[4
]}

Muto, Osamu ^{[5
]}

Sogabe, Susumu ^{[6
]}

Shindo, Ysohiaki ^{[7
]}

Ishiguro, Atsushi ^{[8
]}

Sato, Atsushi ^{[9
]}

Tsuji, Yasushi ^{[10
]}

Dazai, Masayoshi ^{[11
]}

Okuda, Hiroyuki ^{[12
]}

Sasaki, Takahide ^{[13
]}

Harada, Kazuaki ^{[2
]}

Nakano, Shintaro ^{[2
]}

Nakatsumi, Hiroshi ^{[3
]}

Sekiguchi, Mari ^{[14
]}

Sakata, Yuh ^{[15
]}

Sakamoto, Naoya ^{[3
]}

Komatsu, Yoshito ^{[2
]}

机构：

[1] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Japan

[2] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

[4] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[5] Japanese Red Cross Akita Hosp, Dept Med Oncol, Akita, Japan

[6] KKR Sapporo Med Ctr, Dept Med Oncol, Sapporo, Hokkaido, Japan

[7] Nakadori Gen Hosp, Dept Surg, Akita, Japan

[8] Teine Keijinkai Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[9] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan

[10] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[11] Sapporo Med Ctr NTT EC, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[12] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[13] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan

[14] Hokkaido Gastrointestinal Canc Study Grp, Data Ctr, Sapporo, Hokkaido, Japan

[15] Misawa City Hosp, Misawa, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.628

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO26-5

引用

页码：S314 / S314

页数：1

共 50 条

[21] Ramucirumab: second-line therapy for gastric cancer
Sasako, Mitsuru
LANCET ONCOLOGY, 2014, 15 (11): : 1182 - 1184
[22] Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed
Schmid, KE
Kornek, GV
Schüll, B
Raderer, M
Lenauer, A
Depisch, D
Lang, F
Scheithauer, W
ONKOLOGIE, 2003, 26 (03): : 255 - 258
[23] A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer
Hironaka, Shuichi
Kadowaki, Shigenori
Izawa, Naoki
Nishina, Tomohiro
Yamanaka, Takeharu
Minashi, Keiko
Muro, Kei
Sunakawa, Yu
Kajiwara, Takeshi
Hayashi, Yuichiro
Kawakami, Yutaka
Nakajima, Takako Eguchi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[24] The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)
Kadowaki, S.
Sakai, D.
Kawabata, R.
Hara, H.
Yasui, H.
Takahashi, M.
Hirao, M.
Imai, H.
Minashi, K.
Kawakami, T.
Satake, H.
Matsuyama, J.
Sakamoto, Y.
Sawada, K.
Kataoka, M.
Kawakami, H.
Shimokawa, T.
Boku, N.
Satoh, T.
ANNALS OF ONCOLOGY, 2023, 34 : S1317 - S1318
[25] Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer
Alonso, V
Escudero, P
Zorrilla, M
Isla, MD
Herrero, A
Mayordomo, JI
Martinez-Trufero, J
Sáenz, A
Tres, A
Antón, A
EUROPEAN JOURNAL OF CANCER, 2001, 37 (18) : 2385 - 2391
[26] Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).
Hara, Hiroki
Shoji, Hirokazu
Takahari, Daisuke
Esaki, Taito
Machida, Nozomu
Nagashima, Kengo
Aoki, Kazunori
Honda, Kazufumi
Miyamoto, Takahiro
Boku, Narikazu
Kato, Ken
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[27] Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer
Rino, Yasushi
Yukawa, Norio
Sato, Tsutomu
Oshima, Takashi
Tanabe, Hiroyasu
Yamamoto, Yuji
Matsukawa, Hiroshi
Shiraishi, Ryuji
Imada, Toshio
Masuda, Munetaka
MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (04) : 749 - 752
[28] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric cancer who previously treated with first-line nivolumab plus chemotherapy
Jeon, Youngkyung
Jeong, Sun Young
Jang, Jaeyeon
Jung, Ye Ji
Choi, Daeho
Hong, Joohyun
Kim, Seung Tae
Kang, Won Ki
Lee, Jeeyun
CANCER RESEARCH, 2023, 83 (07)
[29] Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
Qu, Jinglei
He, Xin
Luo, Ying
Yu, Ping
Chen, Ying
Liu, Jing
Wang, Xin
Wang, Chang
Liang, Tingting
Bai, Yuxian
Han, Yu
Man, Li
Leng, Chuanchun
Zhou, Caiyun
He, Lijie
Liu, Yunpeng
Qu, Xiujuan
FRONTIERS IN ONCOLOGY, 2023, 13
[30] Is ramucirumab still the only second-line treatment in metastatic gastric cancer?
El Gharib, Khalil
Kourie, Hampig Raphael
PHARMACOGENOMICS, 2020, 21 (17) : 1203 - 1206

← 1 2 3 4 5 →